[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pliant Therapeutics Inc (PLRX)

Pliant Therapeutics Inc (PLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,917
  • Shares Outstanding, K 61,915
  • Annual Sales, $ 0 K
  • Annual Income, $ -149,340 K
  • EBIT $ -156 M
  • EBITDA $ -151 M
  • 60-Month Beta 1.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.41

Options Overview Details

View History
  • Implied Volatility 170.05% (+0.93%)
  • Historical Volatility 47.41%
  • IV Percentile 28%
  • IV Rank 27.94%
  • IV High 608.65% on 01/08/26
  • IV Low 0.00% on 09/03/25
  • Expected Move (DTE 16) 0.2210 (18.49%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 2.85
  • Today's Open Interest 1,663
  • Open Int (30-Day) 4,978
  • Expected Range 0.9740 to 1.4160

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.36
  • Number of Estimates 3
  • High Estimate $-0.31
  • Low Estimate $-0.38
  • Prior Year $-0.92
  • Growth Rate Est. (year over year) +60.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1400 +4.39%
on 03/30/26
1.3800 -13.77%
on 04/17/26
+0.0200 (+1.71%)
since 03/27/26
3-Month
1.0900 +9.17%
on 02/05/26
1.4350 -17.07%
on 03/13/26
-0.0500 (-4.03%)
since 01/29/26
52-Week
1.0900 +9.17%
on 02/05/26
1.9500 -38.97%
on 10/27/25
-0.2900 (-19.59%)
since 04/29/25

Most Recent Stories

More News
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months  Data highlighted in oral presentation at AACR’s Clinical...

PLRX : 1.1900 (-1.65%)
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based...

PLRX : 1.1900 (-1.65%)
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication...

PLRX : 1.1900 (-1.65%)
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based...

PLRX : 1.1900 (-1.65%)
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

One complete response and three partial responses observed  in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment...

PLRX : 1.1900 (-1.65%)
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics,...

PLRX : 1.1900 (-1.65%)
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025...

PLRX : 1.1900 (-1.65%)
Pliant Therapeutics (PLRX) was downgraded to a Sell Rating at J.P. Morgan

Pliant Therapeutics received a Sell rating and price target from J.P. Morgan analyst Brian Cheng today. The company’s shares closed yesterday at $1.49.Elevate Your Investing Strategy: Take advantage...

PLRX : 1.1900 (-1.65%)
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the...

PLRX : 1.1900 (-1.65%)
Pliant Therapeutics Provides Update on BEACON-IPF

PLRX : 1.1900 (-1.65%)

Business Summary

Pliant Therapeutics Inc. is a late-stage biopharmaceutical company which involved in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. The company's lead product candidate includes bexotegrast. Pliant Therapeutics Inc., formerly known as PLANT THERAPEUT, is based...

See More

Key Turning Points

3rd Resistance Point 1.2633
2nd Resistance Point 1.2467
1st Resistance Point 1.2283
Last Price 1.1900
1st Support Level 1.1933
2nd Support Level 1.1767
3rd Support Level 1.1583

See More

52-Week High 1.9500
Fibonacci 61.8% 1.6215
Fibonacci 50% 1.5200
Fibonacci 38.2% 1.4185
Last Price 1.1900
52-Week Low 1.0900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.